ACT2 Project
University of Birmingham (UoB) is the sponsor of ACT2 (Allogeneic Chondrocyte Therapy - A phase 2a study), an MRC funded project (MR/V027670/1). The study commenced in 2021 with the aim to develop and manufacture an allogeneic chondroprogenitor cell therapy from fresh osteochondral allografts in order to treat cartilage lesions in a single surgery. The study requires a manufacturing facility that can work with the research team to develop and validate the manufacturing process of the cell therapy product to a stand...
Buyer
THE UNIVERSITY OF BIRMINGHAM
Value
£617,002
Published
8 May 2024
Closes
8 May 2024
Procurement details
Source
Find a Tender
Region
Birmingham
Procurement method
Limited
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85121200
Medical specialist services
Lots
Lot 1 ACT2 Project
£617,002
Our decision to exclusively source the OsCell laboratory to manufacture the chondrocyte therapy is founded on several irrefutable factors. The OsCell Laboratory is the only GMP facility within the UK who currently manufacture a GMP compliant chondrocyte therapy for clinic use. It is the most experienced laboratory in the UK for the manufacture of chondrocyte...
Delivery: United Kingdom
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.